वैकल्पिक उत्पाद विश्लेषण
आपकी अनुमति से हम गोपनीयता-सीमित विश्लेषण का उपयोग करके समझते हैं कि कौन-सी शोध यात्राएँ उपयोगी हैं। हम विज्ञापन ट्रैकर या सत्र रिकॉर्डिंग नहीं चलाते। आप यह विकल्प प्राथमिकताओं में बदल सकते हैं। पढ़ें गोपनीयता नीति.
Zoetis Inc.'s published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $32.9B | |
|---|---|---|
| Revenue (ttm) | 9.5B | |
| Net income (ttm) | 2.6B | |
| EPS (ttm) | $6.13 | |
| Shares out | 413.2M | |
| P/E (trailing) | 12.7x | |
| P/E (forward) | 12.0x | |
| Dividend | $2.12 (2.73%) | |
| Volume | 2,035,417 | |
| Beta | 0.74 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $7.78B | $8.08B | $8.54B | $9.26B | $9.47B | +5.0% |
| Gross profit | $5.31B | $5.48B | $5.83B | $6.40B | $6.67B | +5.9% |
| Operating income | $2.72B | $2.89B | $3.19B | $3.38B | $3.58B | +7.1% |
| Net income | $2.04B | $2.11B | $2.34B | $2.49B | $2.67B | +7.0% |
| EPS (diluted) | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 | +9.0% |
| EBITDA | $3.17B | $3.36B | $3.69B | $3.87B | $4.07B | +6.4% |
| R&D | $508.0M | $539.0M | $614.0M | $686.0M | $698.0M | +8.3% |
| SG&A | $2.00B | $2.01B | $2.15B | $2.32B | $2.38B | +4.4% |
Recent company headlines from major financial publishers.
In the Bull scenario, veterinary clinic foot traffic rebounds swiftly while international uptake of novel pain monoclonal antibodies Lenivia and Portela exceeds expectations. Dermatology pricing remains resilient as veterinary switching barriers limit competitor share gains. Operating margins expand through operating leverage, and active share repurchases drive sustained compound EPS growth annually.
In the Base scenario, FY2026 revenue reflects the reset guidance range ($9.12B to $9.32B) with EPS of $6.21, before accelerating to 2.51% revenue growth and $6.52 EPS in FY2027. Operating margins normalize to 38.5% by FY2030, while free cash flow generation enables sustained share count reduction of ~1% per year.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 7.7% | $104 | $107 | $110 | $114 | $117 |
| 8.2% | $97.3 | $99.5 | $102 | $105 | $108 |
| 8.7% | $91.6 | $93.4 | $95.5 | $97.7 | $100 |
| 9.2% | $86.7 | $88.2 | $89.9 | $91.7 | $93.8 |
| 9.7% | $82.4 | $83.7 | $85.1 | $86.7 | $88.3 |
Upcoming earnings date and setup when available.
हर महीने प्रकाशित शोध संस्करण की रेटिंग। रेटिंग विश्लेषण की तारीख की कीमत की तुलना उचित मूल्य से करती है; यह इस बात का रिकॉर्ड नहीं है कि आकलन सही निकला या नहीं।
| वर्ष | जन॰ | फ़र॰ | मार्च | अप्रैल | मई | जून | जुल॰ | अग॰ | सित॰ | अक्टू॰ | नव॰ | दिस॰ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
